TABLE 2.
Comparison of prostate cancer diagnosis
| Performance parameter | AP series (n = 86)* | RP series (n = 40)* | ||
|---|---|---|---|---|
| SB | TAB | SB | TAB | |
| Overall cancer detected | 28 (33%) | 47 (55%) | 24 (60%) | 35 (88%) |
| Clinically threatening cancer detected* | 21 (66%) | 29 (91%) | 21 (66%) | 31 (97%) |
| Clinically non-threatening cancer detected** | 7 (13%) | 18 (33%) | 3 (38%) | 4 (50%) |
| Sensitivity (for detecting threatening cases) | 66% | 91% | 66% | 97% |
| Specificity (not detecting non-threatening cases) | 87% | 67% | 63% | 50% |
| PPV (detected cases are clinically threatening) | 75% | 62% | 88% | 89% |
| NPV (not detected cases are non-threatening) | 81% | 92% | 31% | 80% |
*
32 patients had clinically-threatening cancer in each series
**
54 patients in AP series and 8 patients in RP series had clinically non-threatening cancer
AP = autopsy prostates; RP = radical prostatectomy; SB = sextant biopsy; TAB = transrectal anterior biopsy; PPV = positive predictive values; NPV = negative predictive values